Investors in Health

Birk Venture is a company based in Oslo, Norway, dedicated to transforming unique innovations and technologies into successful businesses in the healthcare sector. They focus on leveraging cutting-edge technologies in life science to meet the increasin.

Sandwater: Regenerating resources, vitalizing healthcare & education, and improving life through technology. Supporting entrepreneurs with capital, experience, and connections for lasting positive impact,.Sandwater is a collaborative investment community with a core team at the center with passion and competence to co-create, develop and contribute to meaningful missions together with dedicated founders and great teams

Easo Ventures is a Basque Private Venture Capital Company created with the aim of supporting people and companies that have a clear growth project, providing investment, advice and experience. They focus on partnering with innovative projects that demonstrate clear growth potential and are in their initial phases of development, led by capable entrepreneurs. Their offerings include an Acceleration Program hosted at BerriUp and an investment amounting to €50,000, with further details accessible at BerriUp.com. Moving into Phase 1, they prioritize companies equipped with a well-defined growth strategy and a proven business model, supported by a capable team capable of managing and expanding the project. In this phase, investments range from €100,000 to €1 million, complemented by comprehensive support and advisory services provided by their experienced team.

Myelin VC is Investing in companies that accelerate collective intelligence. They collaborate with visionary outliers to pioneer the unimaginable, investing in founders whose ideas shape a future they envision living in. Their investment strategy spans across industries, from seed funding to Series A, supporting innovative ventures poised to disrupt and redefine their respective fields.

Columbus is a Spanish investment management company that focuses on generating high returns through the Columbus Innvierte Life Science fund. This fund targets seed-stage investments in established private companies within the healthcare and life sciences sectors. The company boasts a robust investment team with international experience and a proven track record in identifying innovative excellence originating from Spanish academic institutions. COLUMBUS VENTURE PARTNERS, SGEIC, SA leverages its expertise in company building and financing to accelerate commercialization for its portfolio companies. Additionally, it facilitates rapid access to the vibrant UK and Boston/Cambridge biotech/pharma venture capital R&D ecosystem.

CRB is a private venture capital management firm dedicated to health technologies. Founded by a seasoned multi-disciplinary executive team, CRB has successfully launched three prior funds focusing on Biotech (Fund I), Medtech (Fund II), and Digital Health (Fund Nuubo). Currently, CRB is advancing with Fund III (CRB Digital Health III), which specializes in digital health. This fund is supported by a team with extensive experience spanning startups, scaleups, corporates, and public health institutions. Headquartered in Madrid and Barcelona, CRB strategically positions itself with access to Europe's most innovative hubs.

"Additio Investment Group is a global Syndicate of Healthcare & Life Sciences Investors that support high-integrity entrepreneurs with the potential to build great businesses. We pay particular attention to EU based opportunities that are in line with our health/care industry expertise and where we can add direct value, mainly: MedTech, and Digital Health/HealthTech with a particular clinical relevance. Average ticket size of €300-500K. AiG1 (fund 1) has been successfully allocated with a high profile portfolio of 5 companies. Our Partners are committed to hands-on value creation to our Portfolio through capital allocation, expertise and access to a valuable international Network."

Ship2B Ventures is a venture capital firm that invests in impact startups. As impact investors, they are dedicated to achieving triple profitability—economic, social, and environmental. Integrating principles from both venture capital and impact investing realms, they aim to maximize financial returns while deliberately creating, managing, and measuring the positive impact of their investments.

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

The investment firm focuses on early-stage and growth-oriented companies located primarily within the region. They seek businesses with scalable ideas and clear competitive advantages, led by driven entrepreneurs willing to take significant risks. Emphasizing sustainability, they assess teams based on their diverse skills and experience. Investments are made through equity, convertible debentures, or Crown loans, with a preference for initiatives linked to growth in Halland and collaborations with Halmstad University. Initial investments typically start at SEK 500,000, with a maximum amount per company limited to one additional investment. Crown loans are offered up to SEK 500,000 annually per company, capped at SEK 250,000. Their investment strategy includes planning for potential exits within a six-year timeframe.

They partner with entrepreneurs and scientists who challenge conventional thinking and tackle complex problems. Their focus is on investing in innovative solutions with the potential to disrupt market structures. They prioritize businesses that embody agility, scalability, and sustainability in their operations and growth strategies.

Creandum, founded after the dotcom bubble and having thrived through the 2008/9 economic crisis, continues to invest steadily despite recent market conditions, believing top founders can emerge anytime. They've witnessed significant growth in the European tech market over 20 years. Now, they proudly announce the closing of Creandum VII, a €500m fund to support Europe's top Seed and Series A startups. Their disciplined, generalist approach focuses on partnering with the best entrepreneurs to build future global, category-defining companies.